

Rights issue fully underwritten - Resolutions from the Extraordinary General Meeting in Peptonic Medical

Stockholm, November 20, 2015. Peptonic Medical AB (publ) – a company developing pharmaceuticals based on oxytocin – today announced that an extraordinary general meeting was held on the 19th November 2015 in Stockholm. Below follows a summary of resolutions adopted.. For detailed information regarding the resolutions of the extraordinary general meeting, please refer to the Company's website www.peptonicmedical.se.

Resolution on the Board's proposal of a rights issue

The extraordinary general meeting resolved in accordance with the Board's proposal of a rights issue on the following terms:

Increase the Company's share capital by a maximum SEK 809 310.80 by a new issue of 8 093 108 shares with preferential rights for shareholders as set out below.

1. Seven (7) existing shares held on the record date entitle to subscribe for six (6) new shares.

In the event that not all shares are subscribed for by the exercise of subscription rights, the Board shall decide on allotment of shares without the exercise of subscription rights up to the maximum amount of the rights issue. Such allotment shall be made, firstly, to those who have subscribed for shares by exercising subscription rights and who wish to subscribe for additional shares, pro rata in proportion to their subscription by exercising subscription rights, secondly, to others who have notified their interest to subscribe for shares without exercising subscription rights, pro rata in proportion to their subscription. For practical reasons, when resolving on allotment, the Board may resolve that the above-mentioned allotment will be made of a certain minimum number of shares only.

2. The record date for participation in the rights issue with preferential rights (receipt of subscription rights) shall be November 26, 2015.
3. The subscription price for each new share shall be SEK 2.80.
4. Subscription for new shares shall take place during the period from November 27, 2015, up to and including December 11, 2015, or such later date to be decided by the Board. Subscription for shares by the exercise of subscription rights shall be made by simultaneous cash payment. Subscription for shares without exercising subscription rights shall be made on a separate subscription list and be paid in cash within three (3) business days from the date when notice of allotment by the Board has been sent to the subscriber, or such later date as the Board may decide.

All resolutions were adopted unanimously.

The rights issue is fully underwritten

CEO Johan Inborr announced during his presentation that the rights issue is fully underwritten through subscription undertakings, subscriptions without preferential rights from existing shareholders (19.7 MSEK) and underwriting commitments (3 MSEK).

Correction regarding dates of the rights Issue

Peptonic Medical announced on November 5 2015, via a press release, that the last day for trading in the shares including right to participate in the Offer is on November 23 2015 and that the first day of trading in the shares excluding right to participate in the Offer is on November 24 2015.

Correct information regarding the above is that the last day for trading in the shares including right to participate in the Offer is on November 24 2015 and that the first day of trading in the shares excluding right to participate in the Offer is on November 25 2015.

For further information, please contact:

Johan Inborr, CEO

Phone: +46 708 853 893

E-mail: johan.inborr@peptonicmedical.se

About Peptonic Medical AB (publ)

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB (publ)'s mission is to develop safe and effective drugs based on oxytocin.